engleski

Collegium Internationale Neuro-Psychopharmacologicum (C.I.N.P.) XXIIIrd Congress, Montreal, Canada, 23-27 June 2002

The goal of the 23rd Collegium Internationale Neuro-Psychopharmacologicum (C.I.N.P.) Congress was to unite the preclinical knowledge and clinical experience of the basic scientists and psychiatrists, researchers and clinicians into understanding of the neurobiological basis of mental disorders, to critically evaluate the data from in vitro to in vivo animal models, to extrapolate these data, if possible and with caution, into better comprehending of the biological basis of pathophysiology, to improve the treatment of psychiatric disorders, and to achieve total remission, not only a response in patients and to reduce the occurrence of adverse effects of neurotropic drugs. The main topics of the congres were depression, apathy, schizophrenia, PTSD, AD, panic disorders, GAD, attention deficit/hyperactivity disorders, alcoholism, bipolar disorders, eating disorders and suicide. The news were that chronic smoking has some similar effects like the effects of antidepressant in MDD, some new combinations of SSRIs with atypical antypsychotics in the treatment of depression, combinations of SSRI with olanzapine in the treatment of nonpsychotic but treatment resistant PTSD, and some potentially new antidepressants, like SPAs and CRF1 receptor antagonists. The congress focused on the treatment considerations in elderly, the adverse effects of psychotropic drugs, especially effects on plasma lipids and plasma glucose, and cardiovascular effects of psychotropic drugs.

Neuropsychopharmacology; psychotropic drugs; depression; bipolar disorders; eating disorders; PTSD

nije evidentirano